Jack Schuler Buys 13,700 Shares of Biodesix (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler acquired 13,700 shares of Biodesix stock in a transaction on Tuesday, August 11th. The shares were purchased at an average cost of $24.01 per share, for a total transaction of $328,937.00. Following the acquisition, the director owned 540,810 shares in the company, valued at approximately $12,984,848.10. This represents a 2.60% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Biodesix Trading Down 1.8%

Shares of NASDAQ BDSX opened at $23.79 on Friday. Biodesix, Inc. has a twelve month low of $5.26 and a twelve month high of $25.52. The company’s fifty day moving average is $20.33 and its 200-day moving average is $16.13. The stock has a market cap of $250.98 million, a price-to-earnings ratio of -7.50 and a beta of 0.56. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.19. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The business had revenue of $26.86 million for the quarter, compared to analyst estimates of $26.03 million. Equities research analysts predict that Biodesix, Inc. will post -2.68 EPS for the current year.

Institutional Investors Weigh In On Biodesix

A number of institutional investors and hedge funds have recently modified their holdings of the company. Allworth Financial LP acquired a new stake in Biodesix in the 2nd quarter valued at about $112,000. BlackRock Inc. acquired a new stake in shares of Biodesix in the second quarter valued at approximately $970,000. AIGH Capital Management LLC bought a new position in shares of Biodesix during the 2nd quarter worth approximately $15,296,000. GSA Capital Partners LLP acquired a new position in shares of Biodesix during the 2nd quarter worth approximately $1,060,000. Finally, Walleye Capital LLC bought a new stake in Biodesix in the 2nd quarter valued at $1,679,000. 20.96% of the stock is owned by institutional investors.

More Biodesix News

Here are the key news stories impacting Biodesix this week:

• Positive Sentiment: Director Jack W. Schuler purchased an additional 15,000 shares for approximately $367,050 at an average price of $24.47 on August 12. Combined with purchases of 13,700 shares on August 11 and 13,900 shares on August 10, Schuler bought 42,600 shares for roughly $1.03 million over three sessions, increasing his direct ownership to 555,810 shares. The buying may signal confidence in Biodesix’s outlook. SEC insider transaction filing
• Positive Sentiment: Biodesix reported second-quarter adjusted performance that exceeded expectations: EPS was negative $0.71 versus the consensus estimate of negative $0.90, while revenue reached $26.86 million compared with an expected $26.03 million. The earnings call transcript provides additional discussion of the results and outlook. Biodesix Q2 2026 earnings call transcript
• Positive Sentiment: Analyst sentiment remains constructive. Canaccord Genuity raised its price target from $27 to $35 while maintaining a Buy rating, and HC Wainwright reiterated Buy with a $27 target. Roth Capital previously initiated coverage with a Buy rating and a $32 target. The reported consensus target is $31.33, above recent trading levels. Biodesix analyst price-target coverage
• Neutral Sentiment: Institutional ownership activity was mixed but included several new positions and additions, including AIGH Capital Management’s approximately $11.0 million stake and increased holdings by XTX Topco. Institutions own about 21% of BDSX.
• Negative Sentiment: Despite the revenue and EPS beat, Biodesix remains unprofitable, with a negative net margin and analysts forecasting approximately negative $2.68 EPS for the current year. Its debt-to-equity ratio of 5.12 also represents a financial risk, particularly after the stock’s substantial advance toward its 52-week high.

Wall Street Analyst Weigh In

BDSX has been the subject of a number of recent research reports. Weiss Ratings upgraded shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. Roth Capital began coverage on Biodesix in a research report on Wednesday, June 24th. They set a “buy” rating and a $32.00 price target for the company. Canaccord Genuity Group boosted their price target on Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 price objective (up from $26.00) on shares of Biodesix in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Biodesix presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.33.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.